Gland Pharma Ltd.

NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

Download real time

2022.80 6.30 (0.31%)

58.30% Gain from 52W Low

184.1K NSE+BSE Volume

NSE 19 Sep, 2025 3:31 PM (IST)

33,326.9

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

06 Aug 2025

2022.80

0.31%

Strong margin gain boosts PAT by 50% YoY

buy

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) posted revenue in line with our estimate in 1QFY26. However, EBITDA/PAT exceeded our estimates (13%/16% beat).

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.

Gland Pharma Ltd.

06 Aug 2025

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating on the stock with a target price of Rs 1,950/share.

Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.

Gland Pharma Ltd.

04 Feb 2025

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

We maintain our HOLD rating with a target price of Rs 1,580, implying an upside potential of 4%, valuing the company at a PE of 20x for FY27.

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

03 Feb 2025

2022.80

0.31%

New launches and higher milestone income drive margins

buy

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (Gland) delivered a better-than-expected operating performance for the quarter. While revenue came in line, product mix and a higher share of milestone income led to better-than-expected margins in the base business.

Number of FII/FPI investors increased from 203 to 212 in Jun 2025 qtr.

Gland Pharma Ltd.

05 Nov 2024

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

we maintain our HOLD rating with a target price of 1,760, implying an upside potential of ~9.4%, valuing the company at a PE of 26x for FY26.

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.

Gland Pharma Ltd.

07 Aug 2024

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

We have Hold on the stock

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

06 Aug 2024

2022.80

0.31%

Lower milestone income and ROW sales hurt earnings

buy

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) reported a miss on its 1QFY25 earnings, largely due to lower milestone income for the quarter. Further, postponement of the off-take of products by European customers hit 1QFY25 performance.

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

23 May 2024

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

Investing in capacity expansion through Capex reflects the company's commitment to meeting future demand and capturing new opportunities in the market. We have Hold on the stock

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.

Gland Pharma Ltd.

15 Feb 2024

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

China remains a key geographic focus area for the company. Gland has received and launched one product this year. Recommendation: HOLD

Gland Pharma Ltd. has gained 28.07% in the last 6 Months

Gland Pharma Ltd.

08 Nov 2023

2022.80

0.31%

Result Update:Gland Pharma

buy

Hold: Gland Pharma Ltd.

Target

Axis Direct

Stability in the Base Business; Maintain HOLD

Gland Pharma Ltd. has an average target of 2145.00 from 2 brokers.

VOTE: Is Gland Pharma Ltd. worth buying?

215 Votes:

Buy 80.93%

Sell 9.3%

Hold 9.77%

RESEARCH REPORTS

Hold SEE REPORTS >

Buy SEE REPORTS >